Aimmune's peanut allergy treatment could 'change practice' — with safety challenges and a price anything but peanuts
Aimmune Therapeutics $AIMT has detailed the results of its Phase III study of its peanut allergy therapy known as AR101 in the New England Journal of Medicine in an article — and independent assessment — that will likely stoke its supporters as much as the skeptics in the field.
And once it is marketed, if it gets that far, you can expect a severe blowback on the price, considering this is a natural byproduct that also has been used at the same dose that costs virtually nothing to make — but wouldn’t have the same stamp of approval that a product OK’d by the FDA would have.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.